22610-18-0

Usage

Uses

Used in Organic Synthesis:
2-Phenylazetidine is used as a building block in organic synthesis for the preparation of various pharmaceuticals and agricultural chemicals. Its unique structure and reactivity make it a valuable component in the creation of complex organic molecules.
Used in Drug Discovery and Development:
2-Phenylazetidine and its derivatives are utilized in drug discovery and development due to their demonstrated biological activity. 2-Phenylazetidine's potential applications in this field are currently under investigation, highlighting its importance in the search for new therapeutic agents.
Used in Metal-Organic Frameworks:
2-Phenylazetidine has been explored for its potential use as a ligand in metal-organic frameworks. This application takes advantage of the compound's ability to form stable coordination complexes with metal ions, which can be useful in various applications, including catalysis and gas storage.
Used in Asymmetric Synthesis:
As a chiral building block, 2-Phenylazetidine is employed in asymmetric synthesis, a technique crucial for producing enantiomerically pure compounds. This is particularly important in the pharmaceutical industry, where the stereochemistry of a drug can significantly affect its efficacy and safety.

InChI:InChI=1/C9H11N/c1-2-4-8(5-3-1)9-6-7-10-9/h1-5,9-10H,6-7H2

Upstream product

• 5661-55-2 4-phenylazetidin-2-one 
• 100-42-5 styrene 

Downstream Products

• 4360-51-4 cinnamylamine 
• 1609694-26-9 5-chloro-3-((2-phenylazetidin-1-yl)methyl)benzo[d]oxazol-2(3H)-one 
• 1542817-58-2 1-tert-butyl-2-(methyldiphenylsilyl)-2-phenylazetidine-1-carboxylate 
• 1542817-55-9 N-(tert-butoxycarbonyl)-2-phenylazetidine 
• 1312573-21-9 2-(4-chlorophenyl)-1-(2-phenylazetidin-1-yl)ethanone 
• 560080-39-9 2-(4-chlorophenyl)-N-(3,3-diphenylpropyl)acetamide 

Relevant academic research and scientific papers

Easy access to constrained peptidomimetics and 2,2-disubstituted azetidines by the unexpected reactivity profile of α-lithiated N-Boc-azetidines

The reactivity profile of lithiated N-Boc-2-arylazetidines has been investigated filling a gap in the chemistry of this class of four-membered heterocycles. Two unexpected and unprecedented results have been observed: an "ortho-effect" accounting for the regioselective functionalization of the azetidine ring, and self-condensation leading to new and interesting azetidine-based peptidomimetics.

Regioselective functionalization of 2-arylazetidines: Evaluating the ortho-directing ability of the azetidinyl ring and the α-directing ability of the N-substituent

The regioselective lithiation-functionalization of 2-arylazetidines has been explored. The nature of the N-substituent is mainly responsible for a regioselectivity switch. ortho-Lithiation occurred, using hexyllithium as a greener base, in N-alkylazetidines, while α-benzylic lithiation has been observed with N-Boc azetidines.

6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM

The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R 1 to R 4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders

6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.